Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 12.78% is in line with its 5-year average of 13.23%, around the middle of its 5-year range (8.13%–16.60%).
As of the fiscal period ended Wednesday, December 31, 2025. 22.24% above its 12-month average of 10.46%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
12.78%
RETURN ON ASSETS (ROA) AVG TTM
10.46%
RETURN ON ASSETS (ROA) AVG 3Y
11.93%
RETURN ON ASSETS (ROA) AVG 5Y
13.23%
RETURN ON ASSETS (ROA) AVG 10Y
13.13%
RETURN ON ASSETS (ROA) AVG 15Y
14.05%
RETURN ON ASSETS (ROA) AVG 20Y
13.04%
CURRENT VS TTM AVG
+22.24%
CURRENT VS 3Y AVG
+7.15%
CURRENT VS 5Y AVG
-3.43%
CURRENT VS 10Y AVG
-2.67%
CURRENT VS 15Y AVG
-9.02%
CURRENT VS 20Y AVG
-1.99%
SECTOR MEDIAN · HEALTHCARE
5.41%
median of 85 covered companies
CURRENT VS SECTOR MEDIAN
+136.23%
vs the sector median at left
Roche Holding AG
Market Cap
$359.46B
Return on Assets (ROA)
12.78%
TTM Avg
10.46%
3Y Avg
11.93%
5Y Avg
13.23%
Market Cap
$358.76B
Return on Assets (ROA)
4.56%
TTM Avg
4.36%
3Y Avg
6.27%
5Y Avg
6.84%
Market Cap
$369.34B
Return on Assets (ROA)
2.44%
TTM Avg
13.98%
3Y Avg
10.40%
5Y Avg
10.28%
Market Cap
$455.87B
Return on Assets (ROA)
4.67%
TTM Avg
3.16%
3Y Avg
4.61%
5Y Avg
4.90%
Market Cap
$255.15B
Return on Assets (ROA)
9.03%
TTM Avg
7.88%
3Y Avg
6.26%
5Y Avg
4.99%
Market Cap
$235.85B
Return on Assets (ROA)
9.14%
TTM Avg
6.48%
3Y Avg
7.48%
5Y Avg
8.52%
Market Cap
$234.38B
Return on Assets (ROA)
6.17%
TTM Avg
6.31%
3Y Avg
6.46%
5Y Avg
7.20%
Market Cap
$205.42B
Return on Assets (ROA)
19.90%
TTM Avg
20.27%
3Y Avg
22.54%
5Y Avg
48.60%
Market Cap
$193.04B
Return on Assets (ROA)
4.97%
TTM Avg
11.99%
3Y Avg
10.28%
5Y Avg
9.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 12.78% | 10.46% | 11.93% | 13.23% |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 4.56% | 4.36% | 6.27% | 6.84% |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 2.44% | 13.98% | 10.40% | 10.28% |
| AbbVie Inc. (ABBV)vs › | $455.87B | 4.67% | 3.16% | 4.61% | 4.90% |
| AstraZeneca PLC (AZN)vs › | $255.15B | 9.03% | 7.88% | 6.26% | 4.99% |
| Amgen Inc. (AMGN)vs › | $235.85B | 9.14% | 6.48% | 7.48% | 8.52% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 6.17% | 6.31% | 6.46% | 7.20% |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 19.90% | 20.27% | 22.54% | 48.60% |
| Abbott Laboratories (ABT)vs › | $193.04B | 4.97% | 11.99% | 10.28% | 9.45% |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | -6.56% | 7.62% | 7.90% | 6.83% |
ROA
12.8%
ROE
38.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 12.78% |
| 2024-12-31 | 8.13% |
| 2023-12-31 | 12.71% |
| 2022-12-31 | 14.09% |
| 2021-12-31 | 15.09% |
| 2020-12-31 | 16.60% |
| 2019-12-31 | 16.24% |
| 2018-12-31 | 13.37% |
| 2017-12-31 | 11.26% |
| 2016-12-31 | 12.47% |
| 2015-12-31 | 11.70% |
| 2014-12-31 | 12.35% |
| 2013-12-31 | 17.96% |
| 2012-12-31 | 14.72% |
| 2011-12-31 | 15.17% |
| 2010-12-31 | 14.20% |
| 2009-12-31 | 10.44% |
| 2008-12-31 | 11.79% |
| 2007-12-31 | 12.48% |
| 2006-12-31 | 10.59% |
| 2005-12-31 | 9.70% |
| 2004-12-31 | 11.44% |
| 2003-12-31 | 5.16% |
| 2002-12-31 | -6.29% |
| 2001-12-31 | 4.91% |
| 2000-12-31 | 12.44% |
| 1999-12-31 | 8.18% |
| 1998-12-31 | 7.86% |
